NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01458717,Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer,https://clinicaltrials.gov/study/NCT01458717,,COMPLETED,"Previous reports suggest benefit of neoadjuvant chemoradiation treatment for borderline resectable pancreas cancer. This study is a multicenter prospective randomized phase II/III study of neoadjuvant chemoradiation with gemcitabine in patients with borderline resectable pancreas cancer. The study is designed in 2 arms, one with upfront surgery and the other with neoadjuvant chemoradiation therapy.",NO,Pancreatic Cancer,DRUG: Neoadjuvant chemoradiation|PROCEDURE: Upfront surgery,"2-year survival rate, 2-year actual survival outcome, 2-year actual survival outcome","Median survival, calculated from overall survival with Kaplan-Meier method, after at least of 2-years follow up of all participants|1-year survival rate, 1-year actual survival rate, after at least of 1-year follow up of all participants|R0 resection rate, according to pathology report after operation, within 3 weeks after operation|curative resection rate, according to pathology report after operation, within 3 weeks after operation|local recurrence, any point during the follow-up period, within at least 2-years follow up|response rate after neoadjuvant chemoradiation, comparison of imaging study findings at pre- and post-neoadjuvant chemoradiation, within 6 weeks after completion of neoadjuvant chemoradiation|efficacy of imaging study after neoadjuvant chemoradiation, comparison of pathology report and imaging study in patients who completed neoadjuvant chemoradiation, within 3 weeks after operation",,Seoul National University Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,58,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,BorderlinePancreas,2011-11,2018-01,2018-01,2011-10-25,,2018-05-02,"Center for Liver Cancer, National Cancer Center, Goyang, Gyeonggi, 410-769, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, 463-707, Korea, Republic of|Seoul National University Hospital, Seoul, 110-744, Korea, Republic of|Samsung Medical Center, Seoul, 135-710, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of",
